4AP for Carpal Tunnel Syndrome (CTS)
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-90
SponsorJohn Elfar
About this trial
The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can treat carpal tunnel syndrome or delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery.
Eligibility criteria
Qualifiers
Patients diagnosed with non-traumatic carpal tunnel syndrome without any other confounding diagnosis (e.g. cubital tunnel syndrome, cervical nerve compression)
Standard of care EDX testing within 6 months of study enrollment
Cognitive ability to report sensory and motor deficit during examination.
Able to complete twice daily dosing of 4-AP for the entire 6 week treatment period.
Disqualifiers
Inability to complete twice daily dosing during 6 week treatment period.
History of multiple sclerosis, stroke or any other diagnosed neurological disorder
History of hypersensitivity to AMPYRA® or 4-aminopyridine
Current use of aminopyridine medications, including other compounded 4-AP
Trial design
Treatments tested in this trial
- 4-Aminopyridine
- Placebo
Treatment groups
160 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
John Elfar
Lead sponsor
University of Arizona
Sponsor institution
Source ClinicalTrials.gov